| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5571370 | Primary Care Diabetes | 2017 | 8 Pages |
Abstract
Treatment with dapagliflozin in T2DM was associated with reductions in HbA1c, weight and systolic blood pressure over time periods up to 2 years. Changes in these parameters were consistent with those reported in RCTs.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
J. Wilding, C. Bailey, U. Rigney, B. Blak, M. Kok, C. Emmas,